Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.40 |
| ▸ | ACHE | P22303 | 6/20 | 0.40 |
| ▸ | BACE1 | P56817 | 6/20 | 0.40 |
| ▸ | BCHE | P06276 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | KLK1 | P06870 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315981 | 0.86 | ROCK2 (0.52) | CCR3ROCK1ROCK2ACHEBACE1 | |
| SCHEMBL3311418 | 0.85 | CCR3 (0.43) | CCR3CYP19A1ROCK1ROCK2ACHE | |
| SCHEMBL3315397 | 0.85 | ROCK1 (0.53) | CCR3CYP19A1ROCK1ROCK2ACHE | |
| SCHEMBL3317311 | 0.85 | ACHE (0.59) | CCR3ROCK1ROCK2ACHEBACE1 | |
| SCHEMBL3313446 | 0.84 | ROCK2 (0.45) | CCR3ROCK1ROCK2ACHEBACE1 | |
| SCHEMBL3318786 | 0.83 | ROCK1 (0.45) | CCR3ROCK1ROCK2 | |
| SCHEMBL3314072 | 0.83 | CCR3 (0.45) | CCR3ACHEBACE1BCHE | |
| SCHEMBL3313389 | 0.80 | PRMT3 (0.44) | ROCK1ROCK2CCR2 | |
| SCHEMBL3314997 | 0.80 | IKBKB (0.48) | CYP19A1ROCK1ROCK2KDM4EALDH1A1 | |
| SCHEMBL3312072 | 0.77 | ROCK2 (0.44) | ROCK1ROCK2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
| EP-2114920-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008077552-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | CCR3 4377/4885CYP19A1 2264/4885ROCK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.